drugset / Trial / NCT00273871

Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients

NCT00273871

Phase 3 Completed 190 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.

Timeline

Start
2002-01
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide
Subject Tacrolimus Small molecule